(Reuters) – A U.S. administrative court on Thursday rejected a filing by Alvogen Pine Brook Llc for a review challenging patents on Celgene Corp’s blockbuster myeloma drug Revlimid.
The Patent Trial and Appeal Board, a court run by the U.S. patent office, said it was denying Alvogen’s petition for an inter-partes review on the patents of the drug.
Drugmaker Bristol-Myers Squibb Co in January said it would buy Celgene Corporation for about $ 74 billion, to expand its pipeline of cancer drugs.
Revlimid, Celgene’s cancer drug that brought in sales of $ 2.55 billion in the fourth quarter, faces loss of exclusivity beginning 2022 in the United States.
Reporting by Manas Mishra in Bengaluru; Editing by James Emmanuel